Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Clinical Reviews in Allergy & Immunology
Erschienen in: Clinical Reviews in Allergy & Immunology 2/2008

01.04.2008

The Immune Response to Respiratory Syncytial Virus Infection: Friend or Foe?

verfasst von: Robert C. Welliver Sr.

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

The immune response to respiratory syncytial virus (RSV) infection has fascinated and frustrated investigators for decades. After adverse responses to early attempts at vaccination, it became popularly held that disease following infection was related to overly aggressive immune responses. However, recent data illustrate that severe forms of disease are related to inadequate, rather than hyperresponsive, adaptive immune reactions. Thus, recovery from primary (and perhaps later) RSV infection is dependent on the quality of innate immune responses. These findings should have enormous significance to the development of vaccines and antiviral compounds.
Literatur
1.
Pelletier AJ, Mansbach JM, Camargo CA Jr (2006) Direct medical costs of bronchiolitis hospitalizations in the United States. Pediatrics 118:2418–2423PubMed
2.
Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ (1999) Bronchiolitis-associated hospitalizations among U.S. children, 1980–1996. JAMA 282:1440–1446PubMed
3.
Langely JM, LeBlanc JC, Smith B, Wang EE (2003) Increasing incidence of hospitalization for bronchiolitis among Canadian children, 1980–2000. J Infect Dis 188:1764–1767
4.
Stein RT, Sherrill D, Morgan WJ, Holberg CJ, Halonen M, Taussig LM, Wright AL, Martinez FD (1999) Respiratory syncytial virus in early life and risk of wheeze and allergy by 13 years. Lancet 353:541–545
5.
Everard ML (2006) The relationship between respiratory syncytial virus infections and the development of wheezing and asthma in children. Curr Opin Allergy Clin Immunol 6:56–61PubMed
6.
Akinbami LJ, Schoendorf KC (2002) Trends in childhood asthma: prevalence, health care utilization, and mortality. Pediatrics 110:315–322PubMed
7.
Glezen WP, Taber LH, Frank AL, Kasel JA (1986) Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 140:543–546PubMed
8.
Dowell SF, Anderson LJ, Gary HE Jr, Erdman DD, Plouffe JF, File TM Jr, Marston BJ, Breiman RF (1996) Respiratory syncytial virus is an important cause of community-acquired low respiratory infection among hospitalized adults. J Infect Dis 174:456–462PubMed
9.
Walsh EE, Peterson DR, Falsey AR (2004) Risk factors for severe respiratory syncytial virus infection in elderly persons. J Infect Dis 189:233–238PubMed
10.
Whimbey E, Couch RB, Englund JA, Andreeff M, Goodrich JM, Raad II, Lewis V, Mirza N, Luna MA, Baxter B, Tarrand JJ, Bodey GP (1995) Respiratory syncytial virus pneumonia in hospitalized adult patient with leukemia. Clin Infect Dis 21:376–379PubMed
11.
Englund JA, Sullivan CJ, Jordan MC, Dehner LP, Vercellotti GM, Balfour HH Jr (1988) Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Ann Intern Med 109:203–208PubMed
12.
Wohl MEB, Chernick V (1978) Bronchiolitis. Am Rev Respir Dis 118:759–781PubMed
13.
Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH (1969) Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89:422–434PubMed
14.
Levine AM, Whitsett JA (2001) Pulmonary collectins in innate host defense of the lung. Microbes Infect 3:161–166PubMed
15.
Levine AM, Gwozdz J, Stark J, Brune M, Whitsett J, Korfhagen T (1999) Surfactant protein A enhances respiratory syncytial virus clearance in vivo. J Clin Invest 103:1015–1021PubMed
16.
Ghildyal R, Hartley C, Varrasso A, Meanger J, Voeker DR, Anders EM, Mills J (1999) Surfactant protein A binds to effusion glycoprotein of respiratory syncytial virus and neutralizes virion infectivity. J Infect Dis 180:2009–2013PubMed
17.
Hickling TP, Malhotra R, Bright H, McDowell W, Blair ED, Sim RB (2000) Lung surfactant protein A provides a route of entry for respiratory syncytial virus into host cells. Viral Immunol 13:125–135PubMed
18.
Hickling TP, Bright H, Wing K, Gower D, Martin SL, Sim RB, Malhotra R (1999) A recombinant trimeric surfactant protein D carbohydrate recognition domain inhibits respiratory syncytial virus infection in vitro and in vivo. Eur J Immunol 29:3478–3484PubMed
19.
Griese M (2002) Respiratory syncytial virus and pulmonary surfactant. Viral Immunol 15:357–363PubMed
20.
Lahti M, Lofgren J, Marttila R, Renko M, Klaavuniemi T et al (2002) Surfactant protein D gene polymorphism associated with severe respiratory syncytial virus infection. Pediatr Res 51:696–699PubMed
21.
Lofgren J, Ramet M, Renko M, Marttila R, Hallman M (2002) Association between surfactant protein A gene locus and severe respiratory syncytial virus infection in infants. J Infect Dis 185:283–289PubMed
22.
Takeda K, Kaisho T, Akira S (2003) Toll-like receptors. Annu Rev Immunol 21:335–376PubMed
23.
Rudd BD, Burstein E, Duckett CS, Li X, Lukacs NW (2005) Differential role for TLR-3 in respiratory syncytial virus-induced chemokine expression. J Virol 79:3350–3357PubMed
24.
Kurt-Jones EA, Popva L, Kwinn L, Haynes LM, Jones LP et al (2000) Pattern recognition receptors TLR-4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 1:398–401PubMed
25.
Monick MM, Yarovinsky TO, Power LS, Butler NS et al (2003) Respiratory syncytial virus upregulates TLR-4 and sensitizes airway epithelial cells to endotoxin. J Biol Chem 278:53035–53044PubMed
26.
Baggiolini M, Dewald B, Moser B (1997) Human chemokines: an update. Annu Rev Immunol 15:675–705PubMed
27.
Zhang Y, Luxon BA, Casola A, Garofalo RP, Jamalludin M, Brasier AR (2001) Expression of respiratory syncytial virus-induced chemokine gene networks in lower airway epithelial cells revealed by cDNA microarrays. J Virol 75:9044–9058PubMed
28.
Olszewska-Pazdrak B, Casola A, Saito T, Alam R, Crowe SE et al (1998) Cell-specific expression of RANTES, MCP-1, and MIP-1α by lower airway epithelial cells and eosinophils infected with respiratory syncytial virus. J Virol 72:4756–4764PubMed
29.
Noah TL, Becker S (1993) Respiratory syncytial virus-induced cytokine production by a human bronchial epithelial cell line. Am J Physiol 265:L472–L478PubMed
30.
Becker S, Quay J, Soukup J (1991) Cytokine (tumor necrosis factor, IL-6, and IL-8) production by respiratory syncytial virus-infected human alveolar macrophages. J Immunol 147:4307–4312PubMed
31.
Soukup JM, Becker S (2003) Role of monocytes and eosinophils in human respiratory syncytial virus infection in vitro. Clin Immunol 107:178–185PubMed
32.
Sheeran P, Jafri H, Carubelli C et al (1999) Elevated cytokine concentrations in the nasal pharyngeal and tracheal secretions of children with respiratory syncytial virus disease. Pediatr Infect Dis J 18:115–122PubMed
33.
Garofalo RJ, Patti J, Hintz KA, Hill V, Ogra PL, Welliver RC (2001) Macrophage inflammatory protein 1α (not T-helper type 2 cytokines) is associated with severe forms of respiratory syncytial virus bronchiolitis. J Infect Dis 184:393–399PubMed
34.
Haeberle HA, Kuziel WA, Dieterich A, Casola A et al (2001) Inducible expression of inflammatory chemokines in respiratory syncytial virus-infected mice: role of MIP-1α in lung pathology. J Virol 75:878–890PubMed
35.
Welliver RC, Garofalo RP, Ogra PL (2002) Beta-chemokines, but neither T helper type 1 nor T helper type 2 cytokines, correlate with severity of illness during respiratory syncytial virus infection. Pediatr Infect Dis J 21:457–461PubMed
36.
Hull J, Rowlands K, Lockhart E, Moore C, Sharland M, Kwiatkowski D (2003) Variance of a chemokine receptor CCR5 are associated with severe bronchiolitis caused by respiratory syncytial virus. J Infect Dis 188:904–907PubMed
37.
Fiedler MA, Wernk-Dollries K, Stark JM (1995) Respiratory syncytial virus increases IL-8 gene expression in protein release in A549 cells. Am J Physiol 269:L865–L872PubMed
38.
Tsutsumi H, Takeuchi R, Ohsaki M, Seki K, Chiba S (1999) Respiratory syncytial virus infection of human respiratory epithelial cells enhances inducible nitric oxide synthase gene expression. J Leukoc Biol 66:99–104PubMed
39.
Elias JA, Zhu Z, Chupp G, Homer RJ (1999) Airway remodeling in asthma. J Clin Invest 104:1001–1006PubMed
40.
Bitko V, Velazquez A, Yang L, Yang YC, Barik S (1997) Transcriptional induction of multiple cytokines by human respiratory syncytial virus requires activation of MF-kappa B and is inhibited by sodium salicylate and aspirin. Virology 232:369–378PubMed
41.
Thomas LH, Friendland JS, Sharland M, Becker S (1998) Respiratory syncytial virus-induced RANTES production from human bronchial epithelial cells is dependent on nuclear factor-kappa B nuclear binding and is inhibited by adenovirus mediated expression of inhibitor of kappa B alpha. J Immunol 161:1007–1016PubMed
42.
Mastronarde JG, Monick MM, Mukaida N, Matsuhima K, Hunninghake GW (1998) Activator protein-1 is the preferred transcription factor for cooperative interaction with nuclear factor-kappa B in respiratory syncytial virus-infected interleukin 8 gene expression in airway epithelium. J Infect Dis 177:1275–1281PubMed
43.
Chini BA, Fiedler MA, Milligan L, Hopkins T, Stark JM (1998) Essential roles of NF-kappa B and C/EBP in the regulation of intercellular adhesion molecule-1 after respiratory syncytial virus infection of human respiratory epithelial cell cultures. J Virol 72:1623–1626PubMed
44.
Haeberle HA, Takizawa R, Casola A, Brasier AR, Dieterich et al (2002) Respiratory syncytial virus-induced activation of nuclear factor-kappa B in the lung involves alveolar macrophages and Toll-like receptor 4-dependent pathways. J Infect Dis 186:1199–1206PubMed
45.
Noah TL, Henderson FW, Wortman IA et al (1995) Nasal cytokine production in viral acute respiratory infection of childhood. J Infect Dis 171:584–592PubMed
46.
Johnson TR, Hong S, Van Kaer L, Koezuka Y, Graham BS (2002) 10K T cells contribute to the expansion of CD8 (positive) T cells and amplification of antiviral immune responses to respiratory syncytial virus. J Virol 76:4294–4303PubMed
47.
Hull JA, Thomson A, Kwiatkowski D (2000) Association of respiratory syncytial virus bronchiolitis with the interleukin-8 gene region in UK families. Thorax 55:1023–1027PubMed
48.
Smyth RL, Mobbs KJ, O’Hea U, Ashby D, Hart CA (2002) Respiratory syncytial virus bronchiolitis: disease severity, interleukin-8, and virus genotype. Pediatr Pulmonol 33:339–346PubMed
49.
Merolla R, Rebert NA, Tsiviste PT, Hoffmann SP, Panuska R (1995) Respiratory syncytial virus replication in human lung epithelial cells: inhibition by tumor necrosis factor alpha and interferon beta. Am J Respir Crit Care Med 152:1358–1366PubMed
50.
Chipps BE, Sullivan WF, Portnory JM (1993) Alpha-2A-interferon for treatment of bronchiolitis caused by respiratory syncytial virus. Pediatr Infect Dis 12:653–658CrossRef
51.
Welliver T, Garofalo RP, Hintz KH, Avendano L, Sanchez K, Jafri H, Chavez-Bueno S, Ogra PL, McKinney L, Reed J, Welliver RC Sr (2007) Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J Infect Dis 195:1126–1136PubMed
52.
van Schaik SM, Obut N, Enhorning G, Hintz K, Gross K, Hancock GE, Stack AM, Welliver RC (2000) Level of interferon gamma in the pathogenesis of primary respiratory syncytial virus infection in BALB/c mice. J Med Virol 62:257–266PubMed
53.
Everard ML, Swarbrick A, Wrightham M, McIntyre J, Dunkley C, James PD, Sewell HF, Milner AD (1994) Analysis of cells obtained by bronchial lavage of infants with respiratory syncytial virus infection. Arch Dis Child 71:428–432PubMed
54.
Wang S-Z, Xu H, Wraith A, Bowden JJ et al (1998) Neutrophils induce damage to respiratory epithelial cells infected with respiratory syncytial virus. Eur Respir J 12:612–618PubMed
55.
Wang S, Forsyth KD (2000) The interaction of neutrophils with respiratory epithelial cells in viral infection. Respirology 5:1–9PubMed
56.
Becker S, Quay J, Soukup J (1991) Cytokine (tumor necrosis factor, IL-6, and IL-8) production by respiratory syncytial virus-infected human alveolar macrophage. J Immunol 147:4307–4312PubMed
57.
Krishnan S, Craven M, Welliver RC, Ahmad N, Halonen M (2003) Differences in participation of innate and adaptive immunity to respiratory syncytial virus in adults and neonates. J Infect Dis 188:433–439PubMed
58.
Barr FE, Pedigo H, Johnson TR, Shepherd VL (2000) Surfactant protein-A enhances uptake of respiratory syncytial virus by mononcytes and U937 macrophages. Am J Respir Cell Mol Biol 23:586–592PubMed
59.
Neuzil KM, Tang Y, Graham BS (1996) Protective role of TNF-α in respiratory syncytial virus infection in vitro and in vivo. Am J Med Sci 311:201–204PubMed
60.
Hussell T, Pennycook A, Openshaw PJ (2001) Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology. Eur J Immunol 31:2566–2573PubMed
61.
Garofalo R, Kimpen JL, Welliver RC, Ogra PL (1992) Eosinophil degranulation in the respiratory tract during naturally acquired respiratory syncytial virus infection. J Pediatr 120:28–32PubMed
62.
Zelaya C, Orvell EA, Strannegard O (1994) Eosinophil cationic protein in nasopharyngeal secretions in serum of infants infected with respiratory syncytial virus. Pediatr Allergy Immunol 5:100–106
63.
Domachowske JB, Dyer KD, Bonville CA, Rosenberg HF (1998) Recombinant human eosinophil-derived neurotoxin/RNase2 functions as an effective antiviral agent against respiratory syncytial virus. J Infect Dis 177:1458–1464PubMedCrossRef
64.
Domachowske JB, Dyer KD, Adams AG, Leto TL, Rosenberg HF (1998) Eosinophil cationic protein/RNase3 is another RNase A-family ribonuclease with direct antiviral activity. Nucleic Acids Res 26:3358–3363PubMed
65.
Bramley AM, Vitalis TZ, Wiggs BR, Hegele RG (1999) Effects of respiratory syncytial virus persistence on airway responsiveness and inflammation in guinea pigs. Eur Respir J 14:1061–1067PubMed
66.
Wedde-Beer K, Hu C, Rodriguez MM, Piedimonte G (2002) Leukotrienes mediate neurogenic inflammation in lungs of young rats infected with respiratory syncytial virus. Am J Physiol Lung Cell Mol Physiol 282:L1143–L1150PubMed
67.
Welliver RC, Wong DT, Sun M, Middleton E Jr, Vaughan RS, Ogra PL (1981) The development of respiratory syncytial virus-specific IgE and the release of histamine in nasopharyngeal secretions after infection. N Engl J Med 305:841–846PubMedCrossRef
68.
Volovitz B, Welliver RC, DeCastro G, Krystofik D, Ogra PL (1988) The release of leukotrienes in the respiratory tract during infection with respiratory syncytial virus: role in obstructive airway disease. Pediatr Res 24:504–507PubMed
69.
Everard ML, Fox G, Walls AF, Quint D et al (1995) Tryptase and IgE concentrations in the respiratory tract of infants with acute bronchiolitis. Arch Dis Child 72:64–69PubMed
70.
Lambrecht BN, Carro-Muino I, Vermaelen K, Pauwels RA (1999) Allergen induced changes in bone-marrow progenitor and airway dendritic cells in sensitized rats. Am J Respir Cell Mol Biol 20:1165–1174PubMed
71.
Lambrecht BN, Peleman RA, Bullock GR, Pauwels RA (2000) Sensitization to inhaled antigen by intratracheal instillation of dendritic cells. Clin Exp Allergy 30:214–220PubMed
72.
Huh JC, Strickland DH, Jahnsen FL, Turner DJ et al (2003) Bidirectional interactions between antigen-bearing respiratory tract dendritic cells and T cell precede the late phase reaction in experimental asthma: DC activation occurs in the airway mucosa but not in the lung parenchyma. J Exp Med 198:19–30PubMed
73.
Holt PG, Stumbles PA (2000) Characterization of dendritic cell populations in the respiratory tract. J Aerosol Med 13:361–367PubMedCrossRef
74.
Trepicchio WL, Wang L, Bozza M, Dorner AJ (1997) IL-11 regulates macrophage effector function through the inhibition of nuclear factor-kappa B. B J Immunol 159:5661–5670
75.
Gill MA, Palucka AK, Barton T, Ghaffer F, Jafri H, Banchereau J, Ramilo O (2005) Mobilization of plasmacytoid and myeloid dendritic cells to mucosal sites in children with respiratory syncytial virus and other viral respiratory infections. J Infect Dis 191:1105–1115PubMed
76.
Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP (1999) Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 17:189–220PubMed
77.
Anderson JJ, Serin M, Harrop J, Amin S et al (1989) Natural killer cell response to respiratory syncytial virus in the BALB/c mouse model. Adv Exp Med Biol 257:211–220PubMed
78.
Hussell T, Openshaw PJ (1998) Intracellular IFN-γ expression in natural killer cells precedes lung CD8+ T cell recruitment during respiratory syncytial virus infection. J Gen Virol 79:2593–2601PubMed
79.
Hussell T, Openshaw PJ (2000) IL-12-activated NK cells reduce lung eosinophilia to the attachment protein of respiratory syncytial virus but do not enhance the severity of illness in CD8 T cell-immunodeficient conditions. J Immunol 165:7109–7115PubMed
80.
Aberle JH, Aberle SW, Dworzak MN, Mandl CW et al (1999) Reduced interferon-gamma expression in peripheral blood mononuclear cells of infants with severe respiratory syncytial virus disease. Am J Respir Crit Care Med 160:1263–1268PubMed
81.
Bont L, Heijnen CJ, Kavelaars A, van Aalderen WM et al (2001) Local interferon-γ levels during respiratory syncytial virus lower respiratory tract infection are associated with disease severity. J Infect Dis 184:355–358PubMed
82.
Welliver RC, Kaul TN, Putnam TI, Sun M, Riddlesberger K, Ogra PL (1980) The antibody response to primary and secondary infection with respiratory syncytial virus: kinetics of class specific responses. J Pediatr 96:808–813PubMed
83.
McIntosh K, Masters HB, Orr I, Chao RK, Barkin RM (1978) The immunologic response to infection with respiratory syncytial virus in infants. J Infect Dis 138:24–32PubMed
84.
Kaul TN, Welliver RC, Wong DT, Udwadia RA, Riddlesberger K, Ogra PL (1981) Secretory antibody response to respiratory syncytial virus infection. Am J Dis Child 135:1013–1016PubMed
85.
Glezen WP, Paredes A, Allison JE, Taber L, Frank AL (1981) Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group and maternal antibody level. J Pediatr 98:708–715PubMed
86.
Hall CB, Walsh EE, Long CE, Schnabel KC (1991) Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 163:693–698PubMed
87.
The IMpact-RSV Study Group (1998) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102:531–537
88.
Bui RHD, Molinaro GA, Kettering JD, Heiner DC, Imagawa DT, St. Geme JW Jr (1987) Virus specific IgE and IgG for antibodies in serum of children infected with respiratory syncytial virus. J Pediatr 110:87–90PubMed
89.
Rabatic S, Gagro A, Lokar-Kolbas R, Krsulovic-Hresic V, Vrtar Z, Popow-Kraupp T, Drazenovic V, Mlinaric-Galinovic G (1997) Increase in CD23+ B cells in infants with bronchiolitis is accompanied by appearance of IgE and IgG for antibodies specific for respiratory syncytial virus. J Infect Dis 175:32–37PubMed
90.
Russi JC, Delfraro A, Borthagaray MD, Velazquez B, Garcia-Barreno B, Hortal M (1993) Evaluation of immunoglobulin E-specific antibodies and viral antigens in nasopharyngeal secretions in children with respiratory syncytial virus infections. J Clin Microbiol 31:819–823PubMed
91.
Welliver RC, Kaul TN, Ogra PL (1980) The appearance of cell-bound IgE in respiratory tract epithelium after respiratory syncytial virus infection. N Engl J Med 303:1198–1202PubMedCrossRef
92.
Bangham CRM, McMichael AJ (1986) Specific human cytotoxic T cells recognize B-cell lines persistently infected with respiratory syncytial virus. Proc Natl Acad Sci USA 83:9183–9187PubMed
93.
Chiba Y, Higashidate Y, Suga K, Honjo K, Tsutsumi H, Ogra PL (1989) Development of cell-mediated cytotoxic immunity to respiratory syncytial virus in human infants following naturally acquired infection. J Med Virol 28:133–139PubMed
94.
Mbawuike IN, Wells J, Byrd R, Cron SG, Glezen WP, Piedra PA (2001) HLA-restricted CD8+ cytotoxic T lymphocyte, interferon-γ, and interleukin-4 responses to respiratory syncytial virus infection in infants and children. J Infect Dis 183:687–696PubMed
95.
Isaacs D, Bangham CRM, McMichael AJ (1987) Cell-mediated cytotoxic response to respiratory syncytial virus in infants with bronchiolitis. Lancet 2:769–771PubMed
96.
Legg JP, Hussain IR, Warner JA, Johnston SL, Warner JO (2003) Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med 168:633–639PubMed
97.
Cherrie AH, Anderson K, Wertz GW, Openshaw PJM (1992) Human cytotoxic T cells stimulated by antigen on dendritic cells recognize the N, SH, F, M, 22K, and 1B proteins of respiratory syncytial virus. J Virol 66:2102–2110PubMed
98.
van Schaik SM, tristram DA, Nagpal IS, Hintz KM, Welliver RC II, Welliver RC (1999) Increased production of interferon-γ and cysteinyl leukotrienes in virus-induced wheezing. J Allergy Clin Immunol 103:630–636PubMed
99.
Everard ML, Fox G, Walls AF, Quint D, Fifield R, Walters C, Swarbrick A, Milner AD (1995) Tryptase and IgE concentrations in the respiratory tract of infants with acute bronchiolitis. Arch Dis Child 72:64–69PubMed
100.
Sznajer Y, Westcott JY, Wenzel SE, Mazer B, Tucci M, Toledano BJ (2004) Airway eicosanoids in acute severe respiratory syncytial virus bronchiolitis. J Pediatr 145:115–118PubMed
101.
Welliver RC, Hintz KH, Glori M, Welliver RC Sr (2003) Zilutin reduces respiratory illness and lung inflammation during respiratory syncytial virus infection in mice. J Infect Dis 187:1773–1779PubMed
Metadaten
Titel
The Immune Response to Respiratory Syncytial Virus Infection: Friend or Foe?
verfasst von
Robert C. Welliver Sr.
Publikationsdatum
01.04.2008
Verlag
Humana Press Inc
Erschienen in
Clinical Reviews in Allergy & Immunology / Ausgabe 2/2008
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-007-8033-2

Weitere Artikel der Ausgabe 2/2008

Clinical Reviews in Allergy & Immunology 2/2008 Zur Ausgabe

OriginalPaper

Smoking Cessation: Significance and Implications for Children

OriginalPaper

Inflammatory Mediators in the Immunobiology of Bronchopulmonary Dysplasia

OriginalPaper

Exercise-induced Bronchospasm In Children

OriginalPaper

A Review of Non-Cystic Fibrosis Pediatric Bronchiectasis

OriginalPaper

Chronic Inflammation in the Cystic Fibrosis Lung: Alterations in Inter- and Intracellular Signaling

OriginalPaper

Approach to the Patient With Recurrent Infections

Neu im Fachgebiet HNO

16.04.2024 | HNO-Chirurgie | Nachrichten

HNO-Op. auch mit über 90?

16.04.2024 | Tonsillektomie | Nachrichten

Intrakapsuläre Tonsillektomie gewinnt an Boden

15.04.2024 | Hörsturz | Nachrichten

Bilateraler Hörsturz hat eine schlechte Prognose

13.04.2024 | Klinik aktuell | Kongressbericht | Nachrichten

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“
weitere anzeigen

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen